Arista™AH, Medafor's Surgical Hemostatic Technology, Receives Approval for European Market
Minneapolis, Minn., September 19, 2002 - Medafor, Inc., announced today that its breakthrough surgical hemostat, Arista™ AH, has received CE mark for intra-operative surgical applications. The Company will now actively market to a range of surgical indications in Europe through its recently opened international service center in Munich, Germany. READ FULL STORY.

Department Paramedics Begin Using Blood Clotting Agent to Control Profuse Bleeding
Saint Paul, Minn., August 1, 2002 - The Saint Paul Department of Fire and Safety Services Paramedic Units will now use TraumaDEX™ to assist in wound management with severe bleeding in the pre-hospital setting. READ FULL STORY.

FDA Approves Medafor's MPH™ for Management of Surgical and Vascular Access Site Bleeding
Minneapolis, Minn., July 12, 2002 - Medafor, Inc., has received regulatory clearance from the Food and Drug Administration to market its MPH™ (Microporous Polysaccharide Hemospheres) technology for use in sugical and chronic care indications.

Medafor Signs Distribution Agreement with Abbott Animal Health, a Division of Abbott Laboratories
Minneapolis, Minn., June 10, 2002 - Medafor, Inc., a market innovator in the development of advanced hemostasis and wound management technology, announced today that it has signed an exclusive, multi-year agreement with Abbott Laboratories for the distribution of HemaBlock™ "Stop the Bleed" to the veterinary market in the United States and worldwide. READ FULL STORY.

Medafor Signs Distribution Agreement with Emergency Medical Products (EMP)
Minneapolis, Minn., February 12, 2002 - Medafor, Inc., a market innovator in the development of advanced hemostasis and wound management technology, announced today that it has signed an agreement with Emergency Medical Products, Inc., a national leader in the distribution of emergency medical equipment and supplies. READ FULL STORY.